Cargando…
Link between COVID-19 vaccines and myocardial infarction
BACKGROUND: Vaccines for coronavirus disease 2019 (COVID-19) include ChAdOx1-SARS-COV-2 (AstraZeneca), Ad26.COV2.S (Janssen), mRNA-1273 (Moderna), BNT162b2 (Pfizer), BBIBP-CorV (Sinopharm), CoronaVac (Sinovac), and Bharat Biotech BBV152 (Covaxin). AIM: To find the association between COVID-19 vaccin...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561578/ https://www.ncbi.nlm.nih.gov/pubmed/36246837 http://dx.doi.org/10.12998/wjcc.v10.i28.10109 |
_version_ | 1784807976769421312 |
---|---|
author | Zafar, Umema Zafar, Hamna Ahmed, Mian Saad Khattak, Madiha |
author_facet | Zafar, Umema Zafar, Hamna Ahmed, Mian Saad Khattak, Madiha |
author_sort | Zafar, Umema |
collection | PubMed |
description | BACKGROUND: Vaccines for coronavirus disease 2019 (COVID-19) include ChAdOx1-SARS-COV-2 (AstraZeneca), Ad26.COV2.S (Janssen), mRNA-1273 (Moderna), BNT162b2 (Pfizer), BBIBP-CorV (Sinopharm), CoronaVac (Sinovac), and Bharat Biotech BBV152 (Covaxin). AIM: To find the association between COVID-19 vaccines and myocardial infarction (MI). METHODS: This is a systematic review that involved searching databases such as MEDLINE, EMBASE, and PakMediNet after making a search strategy using MeSH and Emtree terms. Eligibility criteria were set, and studies having no mention of MI as a complication of COVID-19 vaccination, protocols, genetic studies, and animal studies were excluded. Data was extracted using a predesigned extraction table, and 29 studies were selected after screening and applying the eligibility criteria. RESULTS: The majority of studies mentioned AstraZeneca (18 studies) followed by Pfizer (14 studies) and Moderna (9 studies) in subjects reporting MI after vaccination. Out of all the studies, 69% reported MI cases after the first COVID-19 vaccination dose and 14% after the second, 44% reported ST-segment elevation MI, and 26% reported non-ST-segment elevation MI. The mortality rate was 29% after MI. CONCLUSION: In conclusion, many studies linked MI to COVID-19 vaccinations, but no definitive association could be found. |
format | Online Article Text |
id | pubmed-9561578 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-95615782022-10-15 Link between COVID-19 vaccines and myocardial infarction Zafar, Umema Zafar, Hamna Ahmed, Mian Saad Khattak, Madiha World J Clin Cases Systematic Reviews BACKGROUND: Vaccines for coronavirus disease 2019 (COVID-19) include ChAdOx1-SARS-COV-2 (AstraZeneca), Ad26.COV2.S (Janssen), mRNA-1273 (Moderna), BNT162b2 (Pfizer), BBIBP-CorV (Sinopharm), CoronaVac (Sinovac), and Bharat Biotech BBV152 (Covaxin). AIM: To find the association between COVID-19 vaccines and myocardial infarction (MI). METHODS: This is a systematic review that involved searching databases such as MEDLINE, EMBASE, and PakMediNet after making a search strategy using MeSH and Emtree terms. Eligibility criteria were set, and studies having no mention of MI as a complication of COVID-19 vaccination, protocols, genetic studies, and animal studies were excluded. Data was extracted using a predesigned extraction table, and 29 studies were selected after screening and applying the eligibility criteria. RESULTS: The majority of studies mentioned AstraZeneca (18 studies) followed by Pfizer (14 studies) and Moderna (9 studies) in subjects reporting MI after vaccination. Out of all the studies, 69% reported MI cases after the first COVID-19 vaccination dose and 14% after the second, 44% reported ST-segment elevation MI, and 26% reported non-ST-segment elevation MI. The mortality rate was 29% after MI. CONCLUSION: In conclusion, many studies linked MI to COVID-19 vaccinations, but no definitive association could be found. Baishideng Publishing Group Inc 2022-10-06 2022-10-06 /pmc/articles/PMC9561578/ /pubmed/36246837 http://dx.doi.org/10.12998/wjcc.v10.i28.10109 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Systematic Reviews Zafar, Umema Zafar, Hamna Ahmed, Mian Saad Khattak, Madiha Link between COVID-19 vaccines and myocardial infarction |
title | Link between COVID-19 vaccines and myocardial infarction |
title_full | Link between COVID-19 vaccines and myocardial infarction |
title_fullStr | Link between COVID-19 vaccines and myocardial infarction |
title_full_unstemmed | Link between COVID-19 vaccines and myocardial infarction |
title_short | Link between COVID-19 vaccines and myocardial infarction |
title_sort | link between covid-19 vaccines and myocardial infarction |
topic | Systematic Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561578/ https://www.ncbi.nlm.nih.gov/pubmed/36246837 http://dx.doi.org/10.12998/wjcc.v10.i28.10109 |
work_keys_str_mv | AT zafarumema linkbetweencovid19vaccinesandmyocardialinfarction AT zafarhamna linkbetweencovid19vaccinesandmyocardialinfarction AT ahmedmiansaad linkbetweencovid19vaccinesandmyocardialinfarction AT khattakmadiha linkbetweencovid19vaccinesandmyocardialinfarction |